Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Yukishige Yamada is active.

Publication


Featured researches published by Yukishige Yamada.


Cancer | 1999

The prognostic significance of amplification and overexpression of c‐met and c‐erb B‐2 in human gastric carcinomas

Masakazu Nakajima; Hidetomo Sawada; Yukishige Yamada; Akihiko Watanabe; Mitsutoshi Tatsumi; Jun Yamashita; Masahiko Matsuda; Teruyuki Sakaguchi; Tomoko Hirao; Hiroshige Nakano

The c‐met and the c‐erb B‐2 protooncogenes belong to a family of tyrosine kinase growth factor receptors. Abnormalities of these oncogenes and protein products have been reported in several cancers. The authors investigated the correlation between clinical factors and amplification or overexpression of the c‐met and/or c‐erb B‐2 gene in Japanese patients with gastric carcinoma patients, with a focus on prognostic significance.


Cancer | 2001

Annexin II overexpression correlates with stromal tenascin‐C overexpression

Koji Emoto; Yukishige Yamada; Hidetomo Sawada; Heisuke Fujimoto; Masatou Ueno; Tomoyoshi Takayama; Kiyoshi Kamada; Akihiko Naito; Shuya Hirao; Yoshiyuki Nakajima

Overexpression of annexin II, a calcium‐dependent phospholipid‐binding protein, has been reported in various carcinomas. One of its ligands is tenascin‐C, an extracellular matrix glycoprotein with predominantly antiadhesive qualities that also has been reported to be a prognostic marker for several carcinomas. In the current study, the authors investigated the correlation between the overexpression of annexin II and tenascin‐C in colorectal carcinoma.


Gastric Cancer | 2002

The prognostic significance of overexpression of the decoy receptor for Fas ligand (DcR3) in patients with gastric carcinomas

Yasushi Takahama; Yukishige Yamada; Koji Emoto; Heisuke Fujimoto; Tomoyoshi Takayama; Masatoh Ueno; Hideki Uchida; Shuya Hirao; Takashi Mizuno; Yoshiyuki Nakajima

Abstract.Abstract.Background: The FasL-Fas system has an important role in mediating immune-cytotoxic killing of cells such as virus-infected or tumor cells. It was recently reported that there is a soluble decoy receptor (DcR3), which binds to FasL and inhibits FasL-induced apoptosis, and certain tumors may escape FasL-dependent immune-cytotoxic attack by expressing a decoy receptor that blocks FasL. We evaluated whether DcR3 has clinical relevance in actual human gastric cancers.Methods:. The expression of DcR3 was investigated by Northern blot analysis in a series of 84 primary gastric carcinomas and compared with clinicopathological features and prognosis. The DcR3 expression level was analyzed and quantified densitometrically. The location of DcR3 mRNA in gastric carcinoma tissue was detected by in situ hybridization.Results: The frequency of DcR3 overexpression was 26% (22 of 84 surgical specimens). The DcR3 expression level was significantly associated with lymph node metastasis and pathological stage, but did not correlate with tumor size, metastatic status, or histological type. In situ hybridization demonstrated that DcR3 mRNA was expressed in tumor cells. When the patients were followed up for 63 months, DcR3 overexpression was found to be associated with a significantly shortened duration of overall survival compared with findings in patients having normal DcR3 expression.Conclusion: The DcR3 decoy receptor for FasL may be involved in the progression of gastric cancer. Further evaluation of these possible roles of DcR3 and the regulation of DcR3 expression in malignant cells will be critically important for the development of new strategies for controlling the growth of malignant cells that escape host immune surveillance.


Cancer Science | 2004

Frequent and preferential infection of Treponema denticola, Streptococcus mitis, and Streptococcus anginosus in esophageal cancers

Michihiro Narikiyo; Chikako Tanabe; Yukishige Yamada; Hiroyasu Igaki; Yuji Tachimori; Hoichi Kato; Manabu Muto; Ruggero Montesano; Hiromi Sakamoto; Yoshiyuki Nakajima; Hiroki Sasaki

Multiple cancers frequently occur in the upper digestive tract. One possible explanation is that specific bacterial infection stimulates the normal epithelium to initiate inflammation and/or promotes carcinogenesis. This study was undertaken to determine which bacterial species is predominantly associated with esophageal cancer. We examined the bacterial diversity in this type of cancer and in the saliva from healthy people by using a culture‐independent molecular method. Here we report the preferential and frequent infection of the oral periodontopathic spirochete Treponema denticola (T. denticola), Streptococcus mitis (S. mitis), and Streptococus anginosus (S. anginosus) in esophageal cancer from different regions of the world, and we also describe the induction of inflammatory cytokines by infection of S. anginosus and S. mitis. Our present data suggest that these three bacteria could have significant roles in the carcinogenic process of many cases of esophageal cancer by causing inflammation and by promoting the carcinogenic process, and that eradication of these three bacteria may decrease the risk of recurrence.


Cancer | 1998

Prognostic value of cyclin E and p53 expression in gastric carcinoma

Teruyuki Sakaguchi; Akihiko Watanabe; Hidetomo Sawada; Yukishige Yamada; Jun Yamashita; Masahiko Matsuda; Masakazu Nakajima; Takeshi Miwa; Tomoko Hirao; Hiroshige Nakano

Cyclins and wild‐type p53 are prime cell cycle regulators and may be involved in tumorigenesis. Cyclin E is a late G1 cyclin and its abnormalities have been reported in several cancers. The authors investigated the correlation between cyclin E expression and progression of gastric carcinoma.


British Journal of Surgery | 2005

Analysis of risk factors for the development of gallstones after gastrectomy

Tsunehiro Kobayashi; Michiyoshi Hisanaga; Hiromichi Kanehiro; Yukishige Yamada; Saiho Ko; Y. Nakajima

The incidence of gallstones is higher in people who have undergone gastrectomy than in the general population, but the cause of this is unknown.


Journal of The American College of Surgeons | 1998

Characteristics and clinical outcome of proximal-third gastric cancer

Teruyuki Sakaguchi; Akihiko Watanabe; Hidetomo Sawada; Yukishige Yamada; Mitsutoshi Tatsumi; Heisuke Fujimoto; Kouji Emoto; Hiroshige Nakano

BACKGROUND It is generally accepted that the prognosis of patients with proximal gastric cancer (PGC) is worse than that of patients with more distal gastric cancer. STUDY DESIGN The aim of this study was to compare the clinical features and outcomes of PGC with those of middle- and distal-third gastric cancers. A total of 646 primary gastric cancers was analyzed as a retrospective study. RESULTS Proximal gastric cancer occurred in 21.8% of the 646 cancers analyzed, and approximately 21% of PGCs had esophageal invasion. The 5-year survival rate for patients with PGC was significantly lower than that of patients with more distal tumors. When the PGC group was divided into patients with esophageal invasion and without esophageal invasion, patients with esophageal invasion had significantly worse outcomes. When corrected for depth of invasion, lesions with esophageal invasion had significantly worse outcomes than those of other sites in T2 curative cancers. Proximal gastric cancer with esophageal invasion was characterized by a larger tumor, deeper penetration, and a higher incidence of lymph node metastasis compared with tumors in other sites, and in multivariate analysis of all curative cases, these variables were independent prognostic factors for survival. The frequency of positive proximal margins of PGC was higher than those of other sites. CONCLUSIONS The relatively poor prognosis associated with PGC is mainly from advanced tumor stages of esophageal invasion. Early detection is the most important strategy to improve the survival of patients with PGC. In addition, aggressive lymph node dissection and chemotherapy for esophageal invasion should be considered even if the tumor invasion is moderate (T2 tumor), and a tumor-free margin is important.


Cancer Gene Therapy | 2006

Small interfering RNA expression vector targeting hypoxia-inducible factor 1 alpha inhibits tumor growth in hepatobiliary and pancreatic cancers

Takashi Mizuno; M Nagao; Yukishige Yamada; Michihiro Narikiyo; Masato Ueno; M Miyagishi; K Taira; Yoshiyuki Nakajima

Hepatobiliary and pancreatic carcinomas are hypovascular tumors that can proliferate under hypoxic conditions. Recent reports have demonstrated that hypoxia-inducible factor 1 alpha (HIF1α) plays an important role in the survival of these cancers. Given these findings, the inhibition of the HIF1α pathway might prove to be a powerful tool in the treatment of these cancers. To inhibit HIF1α expression, we used small interference RNA (siRNA) expression vectors in this study. The transient transfection of siRNA expression vectors significantly reduced both HIF1α mRNA levels (13% of control) and protein levels (41% of control) and significantly inhibited the growth of cancer cell lines (P<0.05). VEGF, Glut1, and aldorase A expressions were also significantly reduced by transfection with these vectors (P<0.05), and we found that these vectors induced apoptosis but not cell cycle arrest. In a subcutaneous tumor model using nude mice, transfected MIA PaCa-2 cells, stably expressing siRNAs, barely formed tumors compared to control (P<0.05). This study thus demonstrates the usefulness of siRNA expression vector in targeting HIF1α and points to a potential clinical role in the treatment of pancreatic and hepatobiliary carcinomas.


Journal of Surgical Oncology | 2008

Clinicopathological and prognostic significance of mucin phenotype in gastric cancer

Kohei Wakatsuki; Yukishige Yamada; Michihiro Narikiyo; Masato Ueno; Tomoyoshi Takayama; Hidetoshi Tamaki; Katsuhiko Miki; Sohei Matsumoto; Koji Enomoto; Tomoyo Yokotani; Yoshiyuki Nakajima

Gastric and intestinal mucin phenotype cell markers are widely expressed in gastric carcinoma cells, irrespective of their tumor histological type. In the present study, we tried to reveal the clinicopathological significance of mucin phenotype in human gastric carcinomas. Moreover, we investigated the clinical significance of RUNX3 in association with mucin phenotype.


Cancer Gene Therapy | 1999

Antisense epidermal growth factor receptor delivered by adenoviral vector blocks tumor growth in human gastric cancer

Tomoko Hirao; Hidetomo Sawada; Fumikazu Koyama; Akihiko Watanabe; Yukishige Yamada; Teruyuki Sakaguchi; Mitsutoshi Tatsumi; Heisuke Fujimoto; Kouji Emoto; Michihiro Narikiyo; Nobuhiko Oridate; Hiroshige Nakano

Epidermal growth factor receptor (EGFR) protein overexpression is commonly found in human gastric cancer, and its gene amplification is known to correlate with poor prognosis in gastric cancer patients. With regard to therapy trials targeting EGFR, it has been reported that stable transfection of EGFR antisense or treatment with antibody against EGFR results in growth suppression of human cancer cells that express high levels of EGFR. We have designed an adenovirus-expressing antisense EGFR and have investigated its effect on the growth of gastric cancer in vitro and in vivo. Following infection with EGFR antisense RNA-expressing adenovirus (Ad-EAS), the cell surface EGFR protein levels of infected cancer cells were markedly reduced, and the in vitro growth of Ad-EAS-infected cells was significantly inhibited relative to control-infected cells in all three gastric cancer cell lines (AGS, KKLS, and MKN28) studied here (P < .0002). In a nude mouse subcutaneous tumor system, in vivo tumor growth of MKN28 was significantly inhibited after Ad-EAS treatment, and inhibition on day 48 was 93% by volume compared with that of untreated controls. These results suggest that an adenoviral vector system targeting the down-regulation of EGFR could be a good candidate for the therapy of gastric cancers that overexpress EGFR.

Collaboration


Dive into the Yukishige Yamada's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Hidetomo Sawada

National Archives and Records Administration

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Tomoaki Yano

Nara Medical University

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Hidetomo Sawada

National Archives and Records Administration

View shared research outputs
Researchain Logo
Decentralizing Knowledge